Aziyo Biologics Leadership

Jerry Riebman, M.D. has served as our Chief Medical Officer since January 2020. Prior to joining Aziyo, Dr. Riebman served as lead to the U.S. Medical Heart Failure Program and the New Product Development team for Amgen Pharmaceuticals, Inc., a biotechnology company, from 2018 to 2020 and Director of External Relations and Advocacy for Amgen Pharmaceuticals in 2018. Dr. Riebman also served as Lead Medical Director of Cardiovascular for Novartis Pharmaceuticals Corporation, a pharmaceutical and healthcare company, from 2014 to 2018, where Dr. Riebman developed and marketed Heart Failure products in the Cardiovascular Therapeutic Area and developed and managed various studies for a heart failure clinical trials program. In 2003, Dr. Riebman co-founded Bay Innovation Group, LLC, an emerging medical device incubator, where he currently serves as Director of Scientific and Medical Affairs. He is also Board certified in Surgery and Thoracic Surgery. Dr. Riebman holds an M.D. from Temple University School of Medicine and a B.A. and an M.A. in Biology from Temple University. Prior to this, he served as Executive Director of Medical Affairs for Ethicon Biosurgery, a Johnson & Johnson Global Surgery Group. Dr. Riebman is the inventor on over 14 medical device patents and has entrepreneurial and operational expertise in the development and commercialization of novel medical product solutions. He was also the founder and executive leader of several successful medical device and product companies. Prior to industry, Dr. Riebman’s clinical experience includes Cardiovascular and Thoracic Surgery practice in academic and community environments, including heart transplantation and heart assist devices. He completed medical studies at Temple University in Philadelphia, and trained in Internal Medicine at NYMC-Metropolitan Hospital Center, NY. He completed General Surgery training at Temple University, followed by a NHLBI research fellowship in the Artificial Heart Lab at the University of Utah, and a Cardiothoracic & Vascular Surgery residency at McGill University in Montreal. Dr. Riebman was board certified in both General Surgery and Thoracic Surgery, and is a Fellow of the American College of Surgeons and the American College of Cardiology.

I am a results-oriented leader with a proven record of success in problem solving and decision-making. I work within companies to drive performance and achievement of departmental objectives, build stronger teams, and execute strategic business development.

-

I believe in growth.

Most businesses are probably looking for growth of some kind- growth in profits, capital, consumers, market share. And that kind of growth is greatly important.

But in my work, I aim to maintain a more personal, constant, ever-evolving growth. I constantly grow my knowledge, my creativity, and my passion.

I’ve also spent the last 20+ years growing the skills and experience to help a business with P&L management, sales improvement, operational planning, business development, financial analysis, and more:

• Have successfully built teams in the hospital market for Aziyo Biologics, MNK, and Ikaria

• Refined messaging strategy and tactics to drive growth in the CV market

• Integral team member in one IPO and two acquisitions including investor presentations and deal development.

• Achieved 2018 NA revenue of +$1B , 8% YoY growth, and $750M Operating Income

• Drove MNK low 9% SGA/% of sales all quarterly and yearly targets 16-19

• Developed a business structure that reduced overall expenses for the team by 15%

• Design, implementation, and management of a billing model that drove an incremental ~$400M revenue in a six year span.

• Approved pricing for all products on over 20 contract bids, and won over 80% of those bids in one year

• Developed successful market incentives which will lead to minimum $30m branded sales increase in one year

Finance and Corporate Development Executive with experience in public and private companies in the technology and life sciences industries.